TRK-950

TRK-950 is an investigational agent whose form is not stated in the registry developed by Toray Industries. Its target is NTRK. ClinicalTrials.gov describes the intervention as: 5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in gastric & gastro-oesophageal junction cancer and melanoma. The largest, NCT06038578, plans to enrol 146 participants with primary completion expected 2026-06-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.